Boston Scientific Co. (NYSE:BSX) Shares Bought by Pathstone Family Office LLC

Pathstone Family Office LLC grew its stake in Boston Scientific Co. (NYSE:BSXFree Report) by 67.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,263 shares of the medical equipment provider’s stock after purchasing an additional 26,296 shares during the quarter. Pathstone Family Office LLC’s holdings in Boston Scientific were worth $3,449,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Koss Olinger Consulting LLC lifted its stake in shares of Boston Scientific by 3.7% in the first quarter. Koss Olinger Consulting LLC now owns 5,322 shares of the medical equipment provider’s stock worth $266,000 after buying an additional 191 shares in the last quarter. Brighton Jones LLC lifted its position in Boston Scientific by 5.4% during the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock worth $211,000 after buying an additional 205 shares in the last quarter. Altfest L J & Co. Inc. increased its position in Boston Scientific by 1.6% during the third quarter. Altfest L J & Co. Inc. now owns 13,298 shares of the medical equipment provider’s stock worth $702,000 after purchasing an additional 208 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Boston Scientific by 6.1% in the 3rd quarter. Lindbrook Capital LLC now owns 3,687 shares of the medical equipment provider’s stock valued at $195,000 after purchasing an additional 211 shares during the last quarter. Finally, Heartland Bank & Trust Co increased its holdings in shares of Boston Scientific by 1.6% during the 3rd quarter. Heartland Bank & Trust Co now owns 13,871 shares of the medical equipment provider’s stock worth $732,000 after buying an additional 223 shares during the last quarter. Institutional investors and hedge funds own 89.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BSX shares. Needham & Company LLC increased their price target on Boston Scientific from $60.00 to $71.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. TD Cowen lifted their price target on shares of Boston Scientific from $58.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Citigroup boosted their price target on shares of Boston Scientific from $65.00 to $71.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Morgan Stanley boosted their target price on Boston Scientific from $58.00 to $61.00 and gave the company an “overweight” rating in a research report on Monday, December 4th. One investment analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $65.55.

Get Our Latest Report on Boston Scientific

Boston Scientific Trading Up 0.7 %

NYSE BSX opened at $65.49 on Friday. Boston Scientific Co. has a 52 week low of $45.92 and a 52 week high of $65.61. The firm has a 50 day moving average of $58.94 and a two-hundred day moving average of $54.67. The stock has a market capitalization of $95.94 billion, a PE ratio of 61.21, a price-to-earnings-growth ratio of 2.28 and a beta of 0.78. The company has a quick ratio of 0.90, a current ratio of 1.42 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSXGet Free Report) last issued its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 16.19% and a net margin of 11.19%. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same quarter last year, the company earned $0.45 EPS. As a group, research analysts expect that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 15,000 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $58.40, for a total transaction of $876,000.00. Following the sale, the executive vice president now owns 56,588 shares in the company, valued at approximately $3,304,739.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Joseph Michael Fitzgerald sold 11,660 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $60.00, for a total transaction of $699,600.00. Following the sale, the executive vice president now owns 173,472 shares in the company, valued at $10,408,320. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 15,000 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $58.40, for a total value of $876,000.00. Following the completion of the transaction, the executive vice president now owns 56,588 shares of the company’s stock, valued at $3,304,739.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,185 shares of company stock worth $2,493,967. Insiders own 0.71% of the company’s stock.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.